МЭКЕЛ Майкл Джон (US),ПАРК Джон И. (US),КАРАГЕОЗЯН Хампар Л. (US),КАРАГЕОЗЯН Викен Х. (US)
申请号：
RU2013153152/15
公开号：
RU2013153152A
申请日:
2012.05.09
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A method of inhibiting αβ integrin, αβ integrin, αβ integrin and αβ integrin, and / or other integrins and / or for inhibiting bFGF production in a human or animal subject, comprising the step of: administering to the subject an effective amount of an RG Cys peptide acid or its derivative. 2. The method according to claim 1, wherein the Cys-acid acid RG peptide or derivative thereof is radioactively labeled and is used to detect a tumor. The method according to claim 1, providing at least one therapeutic or diagnostic effect selected from the group consisting of: regulation of endosomal cathepsins； treating or preventing microbial (e.g., bacterial or viral) infections； treating or preventing the inhibition of angiogenesis； treating or preventing angiogenesis-associated disease； inhibiting angiogenesis or vascularization of tumors or neoplasms； inhibiting the production or suitability of VEGF； inhibiting cell adhesion, migration and / or proliferation； treatment of inflammation； cancer treatment； treatment of metastasis； directing and releasing a therapeutic or diagnostic agent in the tumor； thrombosis treatment； provoking vitreolysis； provoking vitreoretinal detachment； facilitate vitreotomy； facilitating wound healing； radiolabeling of tissues expressing various integrins and the treatment of glaucoma. 4. The method according to claim 1, which provides the treatment of angiogenesis-associated disease or disorder selected from the group consisting of cancer, vascular defect, atherosclerosis, vascular adhesion, edema sclerosis, neovascularization of a corneal transplant, neovascular gl1. Способ ингибирования αβ-интегрина, αβ-интегрина, αβ-интегрина и αβ-интегрина, и/или других интегринов и/или для ингибирования bFGF продукции у субъекта, являющегося человеком или животным, включающий стадию:введения субъекту эффективного количества пептида RG Cys-овой кислоты или его производного.2. Способ по п.1, где пептид RG Cys-овой кислоты или его производное является радиоак
